Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
about
Anti-angiogenic therapies for metastatic colorectal cancerSystemic coagulation parameters in mice after treatment with vascular targeting agents.Current targeted therapies in the treatment of advanced colorectal cancer: a reviewCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerAntiangiogenic mechanisms and factors in breast cancer treatmentNovel therapeutic agents in the treatment of metastatic colorectal cancerEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisPopulation pharmacokinetics of bevacizumab in cancer patients with external validationEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsA fresh look at zebrafish from the perspective of cancer researchAnti-angiogenic agents in metastatic colorectal cancerAddition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesValue of bevacizumab in treatment of colorectal cancer: A meta-analysisAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyIs inflammation the cause of pre-eclampsia?Cancer concepts and principles: primer for the interventional oncologist-part IIImmunotherapy strategies for multiple myeloma: the present and the futureRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerImmunotherapy in human colorectal cancer: Challenges and prospectiveFront-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II studyIncidence and management of bevacizumab-related toxicities in colorectal cancerArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabStroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesisCore-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkersAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisHypertension and maternal-fetal conflict during placental malariaSecond-line systemic therapy for metastatic colorectal cancer.Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsPhase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyTargeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataBevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
P2860
Q24241813-60BB4059-ECA6-4C5C-BB22-7004BDC4EDFBQ25257132-E6061D9E-3AA6-43A1-9296-7F92BF141BFDQ26740067-13674528-6A18-4783-B6A2-14556A604982Q26746067-49BB8900-99C0-4AA1-9E71-3BAED0A6DBF9Q26747666-70DDFF94-DDAD-47A0-BB25-9DB7D4B3CC5BQ26748924-226C5CEC-1322-4C4A-A50C-B9C33B86D53EQ26751226-7557C20E-B1DE-42AC-99EA-14A709661D8BQ26769932-E9A2B81B-4015-4A9F-950A-BD03F0D26F24Q26777704-A371E551-93EE-436F-95F1-69A5950A6B27Q26779580-22CE35F8-BFBC-4F73-9A41-2E5BA9F7193EQ26786618-C6F18BCC-3413-470C-A4F9-4383D6BA4708Q26799700-BD25D27C-58AB-44EE-B131-AC31E616A962Q26801911-6605CBC5-F603-4EC4-9D51-8E22106EC5C8Q26822395-19F29FEF-520A-4E99-9B77-33CB949F8CE9Q26824086-109F0B81-5871-4027-8D6F-7AC2509F9CA5Q26826817-D3438360-6AD3-4B45-925A-B6A2727C2B87Q26849789-1B2ACBBF-C3AA-43CD-8BE1-7019602738DBQ26853604-08F18127-1DDE-47A4-9988-0395ED48D5D9Q27007059-94E900D0-ECC4-40FB-8905-D2BF80D05067Q27010961-EDF5D2CE-345E-4910-BD7B-0B5CA9CCD821Q27021939-C137262B-D45A-4E4E-9224-83D12BAFCB6EQ28068654-DF69674F-77A8-4B01-B109-3494770D8863Q28068788-35D83014-950D-4EE4-ABBB-886AA5A974D2Q28211801-A80B28F2-1AF8-4A7B-9B12-D818DD711989Q28219069-CAABBC3A-09F6-4C7E-BA6D-56C4F7AAFC25Q28219257-BD864EB7-46AF-4176-9C74-2C46BA12C539Q28260997-477BF79E-7B48-4DCC-AA3D-7AF427C746A5Q28474977-DC4F33D6-413F-4D89-B075-29D982E2BE36Q28534015-E48663A4-54AF-4341-BFCB-8B5856381180Q28766797-284F7DA1-CF59-4DCB-923F-AFD125A791FBQ30238760-A67209F3-E163-4357-A69F-707CC1DC526AQ30248296-A4038E83-202B-4DDE-8C9B-DE03F24186C1Q30249335-1249261A-DB07-430A-8BEB-028563222C51Q30358961-D4B07D8C-E0A8-44C0-9C02-F6CEA449CF4FQ30422372-497C9B11-153E-4B13-B2AB-61281FC84594Q30439565-315C06D9-6F1E-4BFB-B201-DAF06CEDF49EQ30441458-25D820D5-5B9A-4CAE-A6B2-53DA8042EFF9Q30455612-E0F9686E-3A4A-4FFD-ACC9-3839F78E04DFQ30862367-D7DD2E94-76E0-4046-9249-821B908FF1B2Q30884552-531F7C1D-F68F-48A9-ACB7-E2CCF6D4C57C
P2860
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase II, randomized trial com ...... metastatic colorectal cancer.
@ast
Phase II, randomized trial com ...... metastatic colorectal cancer.
@en
Phase II, randomized trial com ...... metastatic colorectal cancer.
@nl
type
label
Phase II, randomized trial com ...... metastatic colorectal cancer.
@ast
Phase II, randomized trial com ...... metastatic colorectal cancer.
@en
Phase II, randomized trial com ...... metastatic colorectal cancer.
@nl
prefLabel
Phase II, randomized trial com ...... metastatic colorectal cancer.
@ast
Phase II, randomized trial com ...... metastatic colorectal cancer.
@en
Phase II, randomized trial com ...... metastatic colorectal cancer.
@nl
P2093
P921
P356
P1476
Phase II, randomized trial com ...... metastatic colorectal cancer.
@en
P2093
Emily Bergsland
Fairooz Kabbinavar
Grazyna Lieberman
Herbert I Hurwitz
Louis Fehrenbacher
Neal J Meropol
Susan Griffing
William F Novotny
P356
10.1200/JCO.2003.10.066
P407
P577
2003-01-01T00:00:00Z